Germany · Delayed Price · Currency is EUR ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of EUR 1.95 billion. The enterprise value is 2.47 billion.
| Market Cap | 1.95B |
| Enterprise Value | 2.47B |
Important Dates
The next estimated earnings date is Monday, March 2, 2026.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 984.97M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +25.58% |
| Shares Change (QoQ) | +6.57% |
| Owned by Insiders (%) | 30.02% |
| Owned by Institutions (%) | 15.16% |
| Float | 336.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.70 |
| PB Ratio | -4.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.31 |
| EV / Sales | 34.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.92 |
Financial Position
The company has a current ratio of 5.77
| Current Ratio | 5.77 |
| Quick Ratio | 5.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.65 |
| Interest Coverage | -2.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.89% |
| Return on Invested Capital (ROIC) | -53.22% |
| Return on Capital Employed (ROCE) | -56.46% |
| Revenue Per Employee | 104,549 |
| Profits Per Employee | -441,494 |
| Employee Count | 680 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.74% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -58.74% |
| 50-Day Moving Average | 2.00 |
| 200-Day Moving Average | 2.28 |
| Relative Strength Index (RSI) | 54.39 |
| Average Volume (20 Days) | 853 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.23 |
Income Statement
In the last 12 months, ImmunityBio had revenue of EUR 70.36 million and -297.13 million in losses. Loss per share was -0.35.
| Revenue | 70.36M |
| Gross Profit | 70.05M |
| Operating Income | -222.23M |
| Pretax Income | -297.19M |
| Net Income | -297.13M |
| EBITDA | -208.77M |
| EBIT | -222.23M |
| Loss Per Share | -0.35 |
Balance Sheet
The company has 219.73 million in cash and 734.08 million in debt, giving a net cash position of -514.34 million.
| Cash & Cash Equivalents | 219.73M |
| Total Debt | 734.08M |
| Net Cash | -514.34M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -446.10M |
| Book Value Per Share | -0.45 |
| Working Capital | 232.13M |
Cash Flow
In the last 12 months, operating cash flow was -272.48 million and capital expenditures -4.31 million, giving a free cash flow of -276.79 million.
| Operating Cash Flow | -272.48M |
| Capital Expenditures | -4.31M |
| Free Cash Flow | -276.79M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 99.55% |
| Operating Margin | -315.84% |
| Pretax Margin | -422.38% |
| Profit Margin | n/a |
| EBITDA Margin | -296.71% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.58% |
| Shareholder Yield | -25.58% |
| Earnings Yield | -15.25% |
| FCF Yield | -14.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -9.31 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.31 |
| Piotroski F-Score | 4 |